UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2022

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

I	Form 20-F	\boxtimes	Form 40-F	
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):				
	Yes		No	\boxtimes
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):				
	Yes		No	\boxtimes

On January 3, 2022, CureVac N.V. (the "Company") issued the Company's Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021.

The information in this Form 6-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.

By: /s/ Franz-Werner Haas, LLD, LLM

Chief Executive Officer

Date: January 3, 2022

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

99.1 Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021



CureVac N.V.

Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement

As of June 30, 2021

CureVac N.V.

Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)

	Six months ended June 30,	
	2020	2021
(in thousands of EUR, except per share amounts)	(unaudited)	
Revenue	37,668	32,425
Cost of sales	(5,076)	(53,156)
Selling and distribution expenses	(1,009)	(1,029)
Research and development expenses	(41,768)	(236,267)
General and administrative expenses	(23,725)	(50,651)
Other operating income	7,732	45,234
Other operating expenses	(238)	(214)
Operating loss	(26,416)	(263,658)
Finance income	1,229	7,296
Finance expenses	(10,714)	(8,065)
Loss before income tax	(35,901)	(264,427)
Income tax benefit/ (expense)	1,760	(1,329)
Net loss for the period	(34,141)	(265,756)
Other comprehensive income:		
Foreign currency adjustments	2	(30)
Total comprehensive loss for the period	(34,139)	(265,786)
Net loss per share (basic and diluted)	(0.35)	(1.44)

CureVac N.V.

Interim Condensed Consolidated Statements of Financial Position

(in thousands of EUR)	December 31, 2020	June 30, 2021
		(unaudited)
Assets		
Non-current assets		
Intangible assets	14,146	16,196
Property, plant and equipment	66,605	135,577
Right-of-use assets	33,984	32,527
Other assets	6,322	7,454
Deferred tax assets	445	349
Total non-current assets	121,502	192,103
Current assets		
Inventories	14,531	62,912
Trade receivables	1,014	2,592
Contract assets	808	2,302
Other financial assets	2,619	40,107
Prepaid expenses and other assets	48,289	145,217
Cash and cash equivalents	1,322,593	1,355,812
Total current assets	1,389,854	1,608,942
Total assets	1,511,356	1,801,045
Equity and liabilities		
Equity		
Issued capital	21,655	22,425
Capital reserve	1,334,704	1,726,713
Treasury Shares		(3,022)
Accumulated deficit	(645,069)	(910,825)
Other comprehensive income	57	27
Total equity	711,347	835,318
Non-current liabilities		
Finance liabilities	25,189	26,726
Lease liabilities	26,853	25,825
Contract liabilities	500,061	98,891
Other liabilities	284	284
Total non-current liabilities	552,387	151,726
Current liabilities		
Lease liabilities	3,234	3,143
Trade and other payables	21,685	76,569
Other liabilities	64,326	78,602
Income taxes payable	392	204
Contract liabilities	157,985	655,483
Total current liabilities	247,622	814,001
Total liabilities	800,009	965,727
Total equity and liabilities	1,511,356	1,801,045